HopES Sarcoma Trial
The HopES Sarcoma Trial is seeking patients with Ewing’s sarcoma and advanced sarcomas. Should you be interested in participating in a clinical trial or finding out more about what this trial can do for a loved one, we are happy to help you in your journey.
About Sarcomas and Ewing's Sarcoma
Sarcomas are rare cancers in adults but are more common in children. There are approximately 12,0001 new sarcoma cases annually in the U.S. alone. There are many “subtypes” of sarcoma, as it can arise in many tissue structures throughout the body (nerves, muscles, joints, bone, fat, blood vessels – collectively referred to as the body’s “connective tissues”). Sarcomas are most frequently found in the limbs, as this is where the majority of the body’s connective tissues are found but can also present within the sites of more “common” cancers (e.g., breast sarcoma, stomach sarcoma, lung sarcoma, ovarian sarcoma, etc.). Sarcoma cancers often grow hidden deep in the body and are often diagnosed when the tumor size limits effective treatment options.
Ewing’s sarcoma is a primary bone cancer within a group of cancers known collectively as the Ewing’s sarcoma family of tumors. Ewing’s sarcoma is a type of tumor that forms in the bone or soft tissue. It is a rare type of cancer that is often overlooked and receives minimal recognition and research funding. Although Ewing’s sarcoma is typically a pediatric cancer, (it accounts for 30% of bone cancers in children), it can also be found in adults. The most commonly affected areas include the pelvis, thigh, lower leg, upper arm, and chest wall.
Common Signs and Symptoms
Pain off and on in the affected area, which may be worse at night
Swelling, which may start weeks after the pain
A limp (if sarcoma is in leg)
What Are Clinical Trials?
Clinical trials are research studies that investigate new treatments or new combinations of treatments. Sarcoma clinical trials are necessary to determine whether new treatments developed in the laboratory are beneficial to people living with Ewing’s and sarcomas cancers. The Food and Drug Administration (FDA) reviews and analyzes data from clinical trials to determine whether an investigational treatment should be approved for a specific disease or disorder.
Will I Benefit From Participating?
The study medicine is an investigational cancer metabolism-based compound and you may or may not achieve a clinical benefit. By participating in the HopES Sarcoma Study, you may:
- Take an active role in your own healthcare
- Contribute to medical research and helping to shape the future of medicine
About HopES Sarcoma Trial
About TYME SM-88
SM-88 is an oral investigational modified proprietary tyrosine derivative that is believed to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancer types, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events. Learn more about SM-88 Mechanism of Action.
About the Joseph Ahmed Foundation
Clinical Trial Frequently Asked Questions
An investigational medication has been tested in the laboratory and the U.S. Food and Drug Administration (FDA) is allowing it to be tested in people. It is not approved for sale by the FDA or other government agencies. A clinical trial tests how well an investigational medication works and whether it is safe to use for a specific disease or disorder.
A clinical trial has a structured set of clinic visits, tests, and drug dosing schedule the patient must follow. Information about how you feel and how you are reacting to the study treatment is collected.
Protecting the health and safety of people who take part in clinical trials is the highest priority for clinical researchers throughout the entire study process. All clinical trials follow strict federal guidelines on how volunteers must be treated.
As a result of today’s challenges with COVID-19, and based on the Principal Investigators guidance, eligible patients may be able to take oral SM-88 at home as well as interact with the clinical trial physician through telemedicine remotely. This way we keep all participants in the TYME-88-Panc trial compliant and safe when it comes to COVID-19 guidelines and best practices.
You have the right to leave a clinical trial at any time, for any reason. If you decide to leave a trial, talk to your doctor first. You will want to know how leaving the trial might affect your health and what other treatment options may be available.
More information on this clinical trial can be found on clinicaltrials.gov
Qualified patients will have their approved travel and lodging expenses covered by the sponsors with proof of receipts. Additionally, if the qualified patient is a minor, the sponsors will cover approved travel and lodging expenses for one parent/guardian. Contact us for more information.